腾盛博药-B（BRII-B）日前正式向Vir公司提出要求，主张其移交Elebsiran药物的生产技术及相关权益，并就涉嫌违约行为索赔相应损失。
根据公开声明，腾盛博药-B指控Vir在合作过程中存在违反协议条款的行为。该公司寻求通过法律途径维护自身权益，要求Vir立即移交Elebsiran的完整生产工艺流程。
此次纠纷涉及双方在生物制药领域的合作协议。腾盛博药-B强调，Vir的违约行为已对公司研发进度造成实质性影响。除生产技术移交外，该公司还要求Vir承担因违约导致的全部经济损失。
腾盛博药-B（BRII-B）日前正式向Vir公司提出要求，主张其移交Elebsiran药物的生产技术及相关权益，并就涉嫌违约行为索赔相应损失。
根据公开声明，腾盛博药-B指控Vir在合作过程中存在违反协议条款的行为。该公司寻求通过法律途径维护自身权益，要求Vir立即移交Elebsiran的完整生产工艺流程。
此次纠纷涉及双方在生物制药领域的合作协议。腾盛博药-B强调，Vir的违约行为已对公司研发进度造成实质性影响。除生产技术移交外，该公司还要求Vir承担因违约导致的全部经济损失。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.